MX357227B - Nanoparticulas basadas en lipidos. - Google Patents

Nanoparticulas basadas en lipidos.

Info

Publication number
MX357227B
MX357227B MX2013011231A MX2013011231A MX357227B MX 357227 B MX357227 B MX 357227B MX 2013011231 A MX2013011231 A MX 2013011231A MX 2013011231 A MX2013011231 A MX 2013011231A MX 357227 B MX357227 B MX 357227B
Authority
MX
Mexico
Prior art keywords
compositions
lipid
based nanoparticles
amyloid
liposomal
Prior art date
Application number
MX2013011231A
Other languages
English (en)
Other versions
MX2013011231A (es
Inventor
Annapragada Ananth
L Eriksen Jason
A Tanifum Eric
Dasgupta Indrani
c cook Stephen
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46966277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX357227(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2013011231A publication Critical patent/MX2013011231A/es
Publication of MX357227B publication Critical patent/MX357227B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Abstract

Se proporcionan composiciones de nanopartículas basadas en lípidos. Las composiciones generalmente comprenden conjugados de ligando de unión a amiloide con polímero hidrofílico y lípido, y pueden ser composiciones liposómicas. Las composiciones, incluyendo las composiciones liposómicas, pueden ser útiles para la formación de Imágenes y para el tratamiento de los depósitos de la placa ß-amiloide característicos de la Enfermedad de Alzheimer.
MX2013011231A 2011-04-06 2012-04-06 Nanoparticulas basadas en lipidos. MX357227B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161472605P 2011-04-06 2011-04-06
PCT/US2012/032649 WO2012139080A2 (en) 2011-04-06 2012-04-06 Lipid-based nanoparticles

Publications (2)

Publication Number Publication Date
MX2013011231A MX2013011231A (es) 2015-03-05
MX357227B true MX357227B (es) 2018-07-02

Family

ID=46966277

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011231A MX357227B (es) 2011-04-06 2012-04-06 Nanoparticulas basadas en lipidos.

Country Status (15)

Country Link
US (1) US9801957B2 (es)
EP (2) EP3366313A1 (es)
JP (3) JP6212032B2 (es)
KR (2) KR101973063B1 (es)
CN (1) CN104144708B (es)
AU (3) AU2012239888B9 (es)
BR (1) BR112013025633A2 (es)
CA (1) CA2831480C (es)
DK (1) DK2694116T3 (es)
ES (1) ES2685824T3 (es)
HK (1) HK1203827A1 (es)
MX (1) MX357227B (es)
PL (1) PL2694116T3 (es)
PT (1) PT2694116T (es)
WO (1) WO2012139080A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012139080A2 (en) * 2011-04-06 2012-10-11 Board Of Regents Of The University Of Texas System Lipid-based nanoparticles
BR112014010879A2 (pt) 2012-01-20 2017-06-13 Annapragada Ananth métodos e composições para caracterizar objetivamente imagens médicas
US9512092B2 (en) 2013-12-12 2016-12-06 Albert Einstein College Of Medicine, Inc. Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
KR102409017B1 (ko) * 2014-10-08 2022-06-16 텍사스 칠드런스 하스피탈 리포좀을 이용한 아밀로이드 플라크의 mri 영상화
GB201509934D0 (en) 2015-06-08 2015-07-22 King S College London Nanoparticles
JP7312552B2 (ja) * 2016-05-16 2023-07-21 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ナノ粒子としてのｔＲＮＡ送達用組成物およびその使用方法
WO2018100540A1 (en) * 2016-11-30 2018-06-07 Texas Children's Hospital Hydrophilic fluorinated molecules for liposomal 19f mri probes with unique mr signatures
JP2022523056A (ja) * 2019-01-24 2022-04-21 アルゼカ バイオサイエンシズ、エルエルシー 誤って折りたたまれたタンパク質を画像化するための機能化リポソーム
EP4096722A4 (en) * 2020-01-29 2023-06-28 Texas Children's Hospital Targeted contrast agents for mri of amyloid deposition
US11779664B2 (en) 2020-02-12 2023-10-10 Texas Children's Hospital Targeted contrast agents for MRI of alpha-synuclein deposition
CN115279424A (zh) * 2020-02-12 2022-11-01 德克萨斯儿童医院 用于α-突触核蛋白沉积MRI的靶向对比剂

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331751A (en) * 1980-11-17 1982-05-25 Eastman Kodak Company Electrically photosensitive materials and elements for photoelectrophoretic imaging processes
US5204085A (en) 1985-01-08 1993-04-20 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as X-ray contrast agents
US5674468A (en) 1992-03-06 1997-10-07 Nycomed Imaging As Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons
ZA952485B (en) 1994-03-28 1995-12-15 Nycomed Imaging As Liposomes
US6071532A (en) 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
AU2427601A (en) * 1999-11-30 2001-06-12 Arizona Board Of Regents On Behalf Of The University Of Arizona, The Radiation sensitive liposomes
WO2002028441A2 (en) * 2000-10-04 2002-04-11 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
US6821504B2 (en) * 2001-05-23 2004-11-23 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
EP1480691A4 (en) 2002-03-05 2007-11-28 Univ State Cleveland AGGLOMERATED PARTICLES FOR ADMINISTERING AEROSOL DRUGS
EP1641742A4 (en) 2003-05-01 2006-11-29 Nst Neurosurvival Technologies COMPOUNDS BINDING SELECTIVELY TO MEMBRANES OF APOPTOTIC CELLS
US7208174B2 (en) * 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
US7713517B2 (en) 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
US7803351B2 (en) * 2004-08-20 2010-09-28 Washington University Blood brain barrier permeation peptides
ATE493152T1 (de) * 2004-09-23 2011-01-15 Guerbet Sa Liposomale kontrastmittel für die cest-bildgebung
WO2006126208A2 (en) * 2005-05-26 2006-11-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
WO2007048019A2 (en) * 2005-10-20 2007-04-26 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
US20100062969A1 (en) 2006-04-07 2010-03-11 Hayat Onyuksel Hydrophilic polymer-conjugated lipids for peptide and protein folding disorders
US20090123047A1 (en) 2007-03-21 2009-05-14 Yfantis Spyros A Method and system for characterizing prostate images
EP1982733A1 (en) 2007-04-17 2008-10-22 Bayer Schering Pharma Aktiengesellschaft Use of a contrast agent for magnetic resonance imaging of endoleaks
AU2008278605A1 (en) 2007-07-26 2009-01-29 Nanoscan Imaging, Llc Methods for imaging using improved nanoparticulate contrast agents
CN104274840A (zh) 2007-12-05 2015-01-14 马维尔生物科学公司 纳米级对比剂和使用方法
US20100286067A1 (en) 2008-01-08 2010-11-11 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
ITMI20081052A1 (it) * 2008-06-10 2009-12-11 Univ Milano Bicocca Liposomi in grado di legare efficacemente il peptide beta-amiloide
WO2009152445A1 (en) * 2008-06-13 2009-12-17 Marval Biosciences, Inc. Imaging of atherosclerotic plaques using liposomal imaging agents
US20110208064A1 (en) 2008-07-31 2011-08-25 Ran Chongzhao Curcumin Derivatives for Amyloid-Beta Plaque Imaging
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
JP2012520898A (ja) * 2009-03-19 2012-09-10 マーヴァル バイオサイエンシーズ，インコーポレイテッド 画像化におけるコントラスト強調のための組成物および方法
US9334304B2 (en) * 2009-04-02 2016-05-10 The Johns Hopkins University Self-assembling peptides bearing organic electronic functionality and applications employing the same
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
CA2801182A1 (en) 2010-06-16 2011-12-22 Metabolex, Inc. Gpr120 receptor agonists and uses thereof
WO2012119117A1 (en) 2011-03-02 2012-09-07 Sensulin, Llc Vesicle compositions
WO2012139080A2 (en) 2011-04-06 2012-10-11 Board Of Regents Of The University Of Texas System Lipid-based nanoparticles
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
BR112014010879A2 (pt) 2012-01-20 2017-06-13 Annapragada Ananth métodos e composições para caracterizar objetivamente imagens médicas
WO2013164763A2 (en) 2012-04-30 2013-11-07 Innovative Health Diagnostics A biological complex specific for alzheimer's disease detection in vitro and use thereof
BR112015022226A2 (pt) 2013-03-14 2017-07-18 Celtaxsys Inc inibidores de leucotrieno a4 hidrolase
KR102409017B1 (ko) 2014-10-08 2022-06-16 텍사스 칠드런스 하스피탈 리포좀을 이용한 아밀로이드 플라크의 mri 영상화

Also Published As

Publication number Publication date
AU2012239888A2 (en) 2014-05-08
PT2694116T (pt) 2018-10-12
CN104144708B (zh) 2017-07-28
AU2019246775A1 (en) 2019-10-31
JP2014523854A (ja) 2014-09-18
EP3366313A1 (en) 2018-08-29
HK1203827A1 (en) 2015-11-06
BR112013025633A2 (pt) 2017-08-08
WO2012139080A2 (en) 2012-10-11
EP2694116A4 (en) 2015-06-03
KR101973063B1 (ko) 2019-04-30
US9801957B2 (en) 2017-10-31
JP6212032B2 (ja) 2017-10-18
AU2017232156A1 (en) 2017-10-12
WO2012139080A3 (en) 2014-05-01
EP2694116A2 (en) 2014-02-12
JP2018035167A (ja) 2018-03-08
AU2017232156C1 (en) 2019-10-24
KR102035187B1 (ko) 2019-11-08
AU2017232156B2 (en) 2019-07-11
MX2013011231A (es) 2015-03-05
JP6533813B2 (ja) 2019-06-19
CA2831480A1 (en) 2012-10-11
KR20140074868A (ko) 2014-06-18
ES2685824T3 (es) 2018-10-11
AU2012239888B2 (en) 2017-06-22
DK2694116T3 (en) 2018-09-03
PL2694116T3 (pl) 2018-12-31
CN104144708A (zh) 2014-11-12
US20120258044A1 (en) 2012-10-11
AU2012239888B9 (en) 2017-10-12
EP2694116B1 (en) 2018-06-13
JP2019151664A (ja) 2019-09-12
AU2012239888A1 (en) 2013-11-07
KR20190031334A (ko) 2019-03-25
CA2831480C (en) 2020-09-29

Similar Documents

Publication Publication Date Title
MX2013011231A (es) Nanoparticulas basadas en lipidos.
EP2542255A4 (en) METHOD AND COMPOSITIONS FOR TREATING THE DEGOS SYNDROME
EP2707369A4 (en) COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE
ZA201103806B (en) Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
MX2013010343A (es) Composicion y metodos para el transplante de microbiota de colon.
HK1199099A1 (en) Methods and compositions for the treatment and diagnosis of cancer
MX340055B (es) Metodos y composiciones de nanoparticulas sin priones.
WO2011130164A3 (en) Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
MX359327B (es) Composiciones y sus usos para tratar y prevenir la enfermedad de huntington.
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
IL226377B (en) Preparations of isoflavone nanoparticles and methods for their preparation and use
MX371295B (es) Formación de imágenes por irm de placas amiloides usando liposomas.
EP2297341A4 (en) METHOD AND COMPOSITIONS FOR TREATING MORBUS HUNTINGTON
ZA201205432B (en) Compositions and methods for the diagnosis and treatment of tumor
EP2480687A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF THYROID CANCER
SG11201403272YA (en) Compositions and methods for treating alzheimer's disease
EP2723924A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CANCER
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
HK1199290A1 (en) Methods and compositions for the treatment and diagnosis of breast cancer
WO2012040331A3 (en) Multistage nanoparticles
HK1192726A1 (en) 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases 124--5-
ZA201209452B (en) Gold complexes for use in the treatment of cancer
EP2667896A4 (en) METHOD AND COMPOSITION FOR TREATING MORBUS ALZHEIMER
WO2012153253A3 (en) Aromatic compounds and metal complexes thereof

Legal Events

Date Code Title Description
FG Grant or registration